A Phase 2 Study of Ivonescimab in People With Endometrial and Cervical Cancers

Full Title

A Phase 2 Study of Ivonescimab (bispecific antibody against PD1 and VEGF) For the Treatment of Endometrial (EC) and Cervical (CC) Cancers

Purpose

Researchers want to see how well ivonescimab works as a treatment for endometrial and cervical cancers. The people in this study have endometrial or cervical cancer that keeps growing after treatment.

Ivonescimab works by binding to two proteins. One is found on the surface of cancer cells and the other is on immune system cells. Ivonescimab may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy your tumor. It is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Maria Rubinstein at 646-888-6954.